 French
version 
|
||||||||||||||||||||||||
|
||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||
 |
Portfolio | ||||||||||||||||||||||||||||||
| Onco XL | |||||||||||||||||||||||||||||||
| Founded in 1999  Innovative non invasive cancer tests. ONCO XL focuses on the research and development of innovative tests for early cancer diagnostic. The revolutionary patent protected approach relies on the detection of tumour related altered nucleic acid circulating in patient blood. Tumour detection in human will be also possible by analyzing the increased activity of chromosome subunits. Since 1973, Dr Maurice Stroun and Dr Philippe Anker have demonstrated the existence of extra-cellular nucleic acids which are actively released by living cells. Nucleic acids (DNA and RNA) have been detected in plasma, serum, urine, and other body fluids from healthy subjects as well as in patients. The ability to detect and quantify specific DNA and RNA sequences has opened up the possibility of diagnosis and monitoring of diseases. The development of malignancy is associated with many genetic and epigenetic alterations. These alterations in tumours have also been detected in circulating nucleic acids. The identification of circulating nucleic acids has provided a potential tool for the early diagnosis, monitoring and prognosis of cancer patients. Test studies showing the potential application of circulating nucleic acid have been performed for many tumours, including gastro-intestinal, breast, lung, head and neck, urological, gynecological, and skin. The work of numerous laboratories worldwide has produced more than 500 publications in this field in the past ten years. ONCO XL laboratory, in recent years, has researched general blood tests to detect the presence of a cancer. Subsequent tests will be necessary to determine the actual tumour site in the patient. Tumour cell divides continuously without dying due to increased telomerase activity. We believe that early detection of a tumour in the human body will be possible by analyzing the increased activity of one of the telomerase sub-units. The test is covered by the European and American patents.
|
|
||||||||||||||||||||||||||||||
 |
|||||||||||||||||||||||||||||||
